In September 2026, REGENXBIO and the University of Pennsylvania settled their patent infringement litigation with Sarepta Therapeutics and Catalent over ELEVIDYS, with Sarepta agreeing to pay US$39.0 million and receiving broad freedom to operate on AAVrh74-based gene therapies under specified patents. The settlement not only closes costly legal disputes but also removes a significant patent overhang on ELEVIDYS and related AAVrh74 programs, potentially clarifying Sarepta’s long-term gene...

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sarepta Therapeutics (NASDAQ:SRPT) Trading 6.6% Higher - Should You Buy?

No description provided for this story.

Empowered Funds LLC bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 190,586 shares of the biotechnology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, Sept. 14, at 8:30 a.m. ET. The presentation will be webcast live under the investor relations section of Sarepta’s website at

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a key player in the biotechnology sector, presents an intriguing opportunity for investors with a penchant for high-risk, high-reward ventures. With a market capitalization of $2.2 billion, this U.S.-based company is at the forefront of developing RNA-targeted therapeutics and gene therapies for rare diseases, particularly Duchenne muscular dystrophy (DMD). Currently […] Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a key player in the biotechnology sector, presents an intriguing opportunity for investors with a penchant for high-risk, high-reward ventures. With a market capitalization of $2.2 billion, this U.S.-based company is at the forefront of developing RNA-targeted therapeutics and gene therapies for rare diseases, particularly Duchenne muscular dystrophy (DMD). Currently trading at $20.86, Sarepta’s stock has shown a mild price fluctuation, with a slight dip of 0.03% recently. The stock’s 52-week range of $14.86 to $24.45 highlights its volatility, a common characteristic in the biotech industry driven by clinical trial outcomes and regulatory developments. Despite the absence of a trailing P/E ratio, Sarepta’s forward P/E of 8.12 suggests that the market expects future earnings growth. However, the company’s financial performance has been under pressure, with a revenue decline of 34.30% and a negative EPS of -1.57. These figures reflect the challenges of commercializing breakthrough therapies amidst high R&D expenditures and regulatory hurdles. Return on equity stands at -9.48%, indicating that Sarepta is not currently generating profit from its equity investments. However, the company has managed to maintain a positive free cash flow of $22.1 million, providing some financial flexibility for ongoing research and development efforts. Sarepta does not offer a dividend, which is typical for biotech firms reinvesting earnings into research and development. The lack of a payout ratio further underscores the company’s focus on growth and innovation over immediate shareholder returns. Analyst sentiment on Sarepta is mixed, with eight buy ratings, 11 hold ratings, and five sell ratings. The stock’s average price target of $22.26 suggests a potential upside of 6.72%, appealing to investors willing to ride out the inherent volatility. The target price range of $5.00 to $38.00 highlights divergent views on the stock’s future, reflecting the uncertainty tied to clinical trial outcomes and regulatory approvals. Technical indicators provide further insights. The stock is trading above its 50-day moving average of $17.69, indicating a short-term bullish trend, while the 200-day average of $19.08 suggests longer-term stabilization. An RSI of 52.49 denotes a neutral position, neither overbought nor oversold. Meanwhile, the MACD of 0.88, above the signal line of 0.56, points to potential upward momentum. Sarepta’s pipeline is rich with potential. Its flagship products, including EXONDYS 51, VYONDYS 53, and AMONDYS 45, cater to various mutations of the dystrophin gene in Duchenne patients. Moreover, its gene therapy, ELEVIDYS, and other promising candidates like SRP-9003 and SRP-1001, could significantly enhance its market position if successful. The company’s strategic collaborations with industry leaders like F. Hoffman-La Roche Ltd and academic institutions such as Duke University bolster its research capabilities and provide access to cutting-edge technologies. For investors, Sarepta Therapeutics represents a compelling blend of potential and risk. The company’s dedication to addressing unmet medical needs in rare diseases could yield substantial returns, albeit with the typical unpredictability associated with biotech investments. Investors with a tolerance for volatility and a focus on long-term growth may find Sarepta’s current valuation and future prospects worth considering.

No description provided for this story.

OMERS ADMINISTRATION Corp acquired a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 48,054 shares of the biotechnology company's

Investors are eagerly anticipating new insights from Sarepta Therapeutics’ ongoing mid-stage clinical trials targeting two distinct muscle disorders: facioscapulohumeral muscular dystrophy and myotonic dystrophy. Published Aug 27, 2026 | 3:00 PM EDT Sarepta Therapeutics (SRPT) shares surged by 12% on Thursday, recovering from their July lows as market participants focus on forthcoming clinical trial results. […] Investors are eagerly anticipating new insights from Sarepta Therapeutics’ ongoing mid-stage clinical trials targeting two distinct muscle disorders: facioscapulohumeral muscular dystrophy and myotonic dystrophy. Published Aug 27, 2026 | 3:00 PM EDT Sarepta Therapeutics (SRPT) shares surged by 12% on Thursday, recovering from their July lows as market participants focus on forthcoming clinical trial results. Meanwhile, competitor Capricor Therapeutics encountered a regulatory hurdle with its Duchenne muscular dystrophy (DMD) treatment. Despite this recent rally, Sarepta’s stock remains below its 52-week peak of $25.32 but is positioned to record its strongest weekly performance since late March. Current FDA-Approved Therapies and Future Developments Sarepta currently holds FDA approval for four therapies aimed at Duchenne muscular dystrophy, a debilitating genetic condition characterized by progressive muscle degeneration predominantly affecting young males. Beyond DMD, Sarepta is advancing clinical research in two additional muscle disorders: facioscapulohumeral muscular dystrophy and myotonic dystrophy. Data from these mid-stage trials, expected in the latter half of 2026, will clarify whether the promising effects observed in initial single-dose studies from March persist with repeated administration. Elevidys, Sarepta’s gene therapy for Duchenne muscular dystrophy, remains authorized only for ambulatory patients due to earlier safety concerns linked to liver complications. By the end of 2026, Sarepta aims to complete enrollment in a trial combining Elevidys with enhanced immunosuppressive regimens for non-ambulatory patients, with preliminary results anticipated in early 2027. Additionally, the FDA is scheduled to decide by February 28, 2027, on converting two older Duchenne therapies from accelerated to full approval status. Financial Performance and Leadership Update In the second quarter, Sarepta reported product sales totaling $328.7 million, with Elevidys contributing $98.1 million and the company’s established DMD drugs accounting for $230.6 million. Overall revenue declined to $401.3 million from $611.1 million year-over-year, primarily due to Elevidys’ restricted use following reports of patient fatalities. The company has adjusted its 2026 product sales forecast to a range of $1.2 billion to $1.3 billion, narrowing from the previous $1.2 billion to $1.4 billion estimate. Sarepta also cautioned that third-quarter Elevidys sales might dip below second-quarter figures. Michael Severino, formerly an executive at AbbVie, assumed the role of Sarepta’s CEO on July 28, just ahead of these critical clinical data releases. Regulatory Challenges for Competitors Capricor Therapeutics’ cell therapy for Duchenne muscular dystrophy, Deramiocel, faced a setback when an FDA advisory committee voted 9-3 against the treatment’s efficacy for Duchenne-related cardiac disease on July 29. Subsequently, the FDA extended its decision deadline from August 22 to November 22 after Capricor submitted additional data and requested approval for a narrower indication focusing on arm function. Although both Sarepta and Capricor target Duchenne muscular dystrophy, their therapies differ mechanistically. The delay in Deramiocel’s approval potentially reduces near-term competition, which could benefit Sarepta’s market position. Retail Investor Sentiment and Market Outlook On Stocktwits, retail investor sentiment toward SRPT has shifted from bearish to bullish within the past 24 hours, accompanied by an increase in message volume from low to normal levels. Some users speculate about a potential acquisition of Sarepta, while others express optimism about a significant turnaround for the stock. Year-to-date, SRPT shares have appreciated approximately 2%. SRPT stock remains a focal point for investors tracking advancements in muscular dystrophy treatments. For further reading: TE Stock Surges 9% Following Norway’s Approval of Data Center for Idle Battery Plant For corrections or updates, please contact newsroom[at]stocktwits[dot]com Subscribe to Chart Art Receive a daily cryptocurrency newsletter that combines insightful data analysis with engaging commentary. Learn more about our editorial standards and ethics policy

Sarepta Therapeutics (NASDAQ:SRPT) Trading 15.2% Higher - What's Next?

Sarepta Therapeutics stock has seen a steep share price decline over the past few years, yet on current market multiples it still screens as expensive rather than clearly cheap. With the valuation checks giving a mixed signal, investors are left weighing recent performance against the current pricing. The share price decline of around 84.7% over the past 3 years points to a company where expectations have reset sharply and long term holders have faced heavy losses. Future progress in Sarepta...

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a prominent player in the biotechnology sector, is renowned for its focus on developing RNA-targeted therapeutics and genetic therapies aimed at treating rare diseases. With its headquarters in Cambridge, Massachusetts, the company has been at the forefront of groundbreaking treatments, particularly for Duchenne muscular dystrophy (DMD). Despite its market cap […] Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a prominent player in the biotechnology sector, is renowned for its focus on developing RNA-targeted therapeutics and genetic therapies aimed at treating rare diseases. With its headquarters in Cambridge, Massachusetts, the company has been at the forefront of groundbreaking treatments, particularly for Duchenne muscular dystrophy (DMD). Despite its market cap of $1.98 billion and a diverse portfolio of innovative treatments, Sarepta’s stock has seen its share of volatility, making it a focal point for investors seeking growth in the healthcare sector. Currently, Sarepta’s stock is priced at $18.79, reflecting a slight decrease of 0.02% from the previous trading session. This price is positioned within its 52-week range of $14.86 to $24.45, suggesting a moderate trading range over the past year. The company’s forward P/E ratio stands at a compelling 7.31, indicating potential undervaluation when compared to the broader market. However, the company lacks a trailing P/E ratio and other traditional valuation metrics like PEG, Price/Book, and Price/Sales, which can be attributed to its current financial position marked by challenges in profitability. Sarepta’s performance metrics reveal certain operational hurdles. The company has experienced a significant decline in revenue growth, down by 34.30%, alongside an EPS of -1.57. These figures underscore the financial strain faced by the company as it invests heavily in R&D to advance its therapeutic offerings. Moreover, the negative Return on Equity (ROE) of -9.48% further highlights the challenges in generating returns for shareholders in the current fiscal environment. Despite these setbacks, Sarepta maintains a positive free cash flow of $22,139,876, which could provide some operational leeway and potential for strategic investments in its pipeline. The analyst community offers a mixed outlook on Sarepta. With 8 buy ratings, 11 hold ratings, and 5 sell ratings, there is a cautious consensus regarding the stock’s immediate prospects. The average target price set by analysts is $22.09, suggesting a potential upside of 17.55% from its current level. This forecast reflects a cautiously optimistic view, though investors should weigh this against the inherent risks associated with high-stakes biopharmaceutical development. From a technical standpoint, Sarepta’s stock is navigating close to its 50-day moving average of $17.29 but remains below the 200-day moving average of $19.02. The RSI (Relative Strength Index) of 44.36 indicates that the stock is neither overbought nor oversold, positioning it in a relatively neutral zone. The MACD (Moving Average Convergence Divergence) of 0.55, with a signal line of 0.27, presents a bullish signal, potentially indicating a positive momentum shift. Sarepta’s strategic collaborations with industry giants like F. Hoffman-La Roche Ltd and Arrowhead Pharmaceuticals, as well as leading research institutions, bolster its R&D capabilities. These partnerships, alongside its robust pipeline of therapies targeting DMD and other genetic disorders, position the company as a significant entity within the biotech landscape. Investors considering Sarepta Therapeutics should carefully assess the balance between its innovative potential and the financial challenges it currently faces. While the 17.55% potential upside presents an enticing opportunity, the company’s path forward is laden with both promise and risk, typical of biotech investments. As Sarepta continues to advance its therapeutic developments, its future performance will largely hinge on successful clinical outcomes and strategic market positioning.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) has been assigned an average recommendation of "Hold" from the twenty brokerages that are currently covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a sell recommendation, six have given a hol

Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 9.2% - What's Next?

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a prominent player in the biotechnology sector, stands out with its innovative approach to rare disease treatment. Focused on RNA-targeted therapeutics and gene therapy, Sarepta is carving a niche in the healthcare industry with its specialized treatments for Duchenne muscular dystrophy (DMD). With a current market capitalization of $1.91 billion […] Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a prominent player in the biotechnology sector, stands out with its innovative approach to rare disease treatment. Focused on RNA-targeted therapeutics and gene therapy, Sarepta is carving a niche in the healthcare industry with its specialized treatments for Duchenne muscular dystrophy (DMD). With a current market capitalization of $1.91 billion and a stock price of $18.1, Sarepta’s market position is further highlighted by its 52-week price range of $14.86 to $24.45. Despite a recent price dip of 0.32 (-0.02%), the stock’s average target price of $22.09 suggests a significant potential upside of 22.03%. A glance at Sarepta’s valuation metrics reveals a Forward P/E ratio of 7.04, indicating that the market expects growth in the near future. However, the absence of a trailing P/E ratio and other valuation metrics like Price/Book and Price/Sales highlights the company’s current focus on strategic growth rather than profitability. The company’s recent performance metrics reveal challenges, with a revenue decline of 34.30% and an EPS of -1.57, reflecting the intense R&D efforts that often characterize biotech firms in the drug development phase. This focus on innovation is further underscored by a negative Return on Equity of -9.48%. Nonetheless, Sarepta’s free cash flow of over $22 million is a positive sign of its ability to finance ongoing projects and potential expansions without immediate reliance on external capital. Sarepta’s therapeutic portfolio includes EXONDYS 51, VYONDYS 53, and AMONDYS 45, each targeting specific gene mutations within the Duchenne muscular dystrophy spectrum. The recent development of ELEVIDYS, an AAV-based gene therapy, marks a significant advancement in the company’s treatment offerings. Additionally, Sarepta’s pipeline includes promising candidates like SRP-9003 and SRP-1001, which are in various stages of clinical trials. From an analyst perspective, Sarepta commands a mixed outlook with 8 buy ratings, 11 hold ratings, and 5 sell ratings. This diverse viewpoint underscores the speculative nature of biotech investments, where advancements in clinical trials can significantly sway market sentiment. Notably, the target price range of $5.00 to $38.00 reflects the high-risk, high-reward potential inherent in the biotech sector. Technical indicators present a mixed picture with a 50-day moving average of $16.99 below the 200-day moving average of $19.14, suggesting potential short-term volatility. However, the Relative Strength Index (RSI) of 27.49 signals that the stock may be oversold, opening opportunities for bargain hunters. The MACD and Signal Line indicators further support the potential for a bullish reversal in the near term. Sarepta’s strategic collaborations with renowned entities such as F. Hoffman-La Roche Ltd and Arrowhead Pharmaceuticals, along with its partnerships with top-tier research institutions, bolster its innovative edge. These alliances not only enhance Sarepta’s research capabilities but also position it favorably in the competitive biopharmaceutical landscape. Investors with an appetite for high-growth opportunities and a tolerance for volatility may find Sarepta Therapeutics an intriguing addition to their portfolios. As the company continues to advance its gene therapy and RNA-targeted treatment landscape, its long-term potential remains promising, albeit with inherent risks typical of the biotechnology industry.

No description provided for this story.

No description provided for this story.

No description provided for this story.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) was the recipient of unusually large options trading activity on Friday. Stock investors purchased 4,625 call options on the stock. This represents an increase of 47% compared to the typical volume of 3,153 call options.

Sarepta Therapeutics Inc (SRPT) reports Q2 2026 GAAP operating income of $13 million and advances siRNA pipeline while navigating Elevidys revenue challenges.Related Stocks: SRPT,

Analyzing Sarepta Therapeutics Inc's Strengths, Weaknesses, Opportunities, and ThreatsRelated Stocks: SRPT,

Sarepta Therapeutics (NASDAQ:SRPT) reported second-quarter 2026 total revenue of $401 million, down 34% from a year earlier, as lower ELEVIDYS sales weighed on results. The company nevertheless posted GAAP operating income of $13 million and non-GAAP operating income of $86 million, while increasing

No description provided for this story.

No description provided for this story.